Insights · Feasibility

Germany and Canada pair deep Crohn's experience with light competition. A registry proxy for country selection.

Two registry numbers give a free first cut at country selection: trials completed (experience) and trials recruiting now (competition). For Phase 2–3 Crohn's disease, Germany and Canada lead; China is the outlier.

Rudiger Mees17 Oct 20265 min readData: ClinicalTrials.gov

Country selection usually starts with a feasibility survey. A first cut can be made earlier, for free, from two registry numbers: how many industry trials a country has completed in the disease (experience) and how many are recruiting there now (competition). For Phase 2–3 Crohn's disease, Germany has 2.4 recruiting trials for every 10 it has completed and Canada 2.8. China has 19.

Quadrant · experience vs competitionReal data

Germany and Canada pair deep Crohn's experience with light competition

020406080100120010203040Completed trials (experience) →Recruiting now (competition) →2.5 per 105 per 10GermanyUnited StatesSpainPolandChinaItalyUnited KingdomCanada
Under 2.9 recruiting per 10 completed2.9–6Over 6
ClinicalTrials.gov API v2, pulled 17 Oct 2026. Industry lead sponsor, interventional, Phase 2–3, condition "Crohn disease", trials with at least one site in the country. Completed = overall status completed (all years); recruiting = recruiting today. Unlabelled blue dots: Belgium, Czechia, France, Hungary, Japan, Netherlands.

How to read the chart

Bottom right is where you want to be: many completed trials, few recruiting now. That suggests investigators who know the protocol burden of Crohn's trials and patients who are not already being competed for. Top left is the opposite: little track record and a crowded present.

Germany (82 completed, 20 recruiting) and Canada (83 completed, 23 recruiting) sit furthest into the good corner. The United States has the deepest experience of all (121 completed) but also the most concurrent trials (36), for a ratio of 3.0. China is the outlier: 19 recruiting trials against 10 completed, a young and now heavily used market.

Ranking · recruiting per 10 completedReal data

Lower is better: competition relative to experience

Germany2.4Canada2.8United States3.0France3.1Hungary3.2Netherlands3.5Czechia3.6Belgium3.6United Kingdom4.0Spain4.2Poland4.3Japan4.4Italy5.3China›19.0
ClinicalTrials.gov API v2, pulled 17 Oct 2026. Same population. China's bar is capped at 10 for readability.

What the proxy cannot see

This is a shortlist tool, not a feasibility survey. It counts trials, not sites or patients. Completed trials include some that ran many years ago. It knows nothing about enrolment speed, standard of care, start-up timelines or reimbursement, all of which can overturn a good ratio. Read it as: where should the feasibility questionnaire go first?

The next step goes one level down: within Germany, which sites have actually run Crohn's trials, and which of them are busy today? The same registry records hold the facility names, and Comphas turns them into a site-level board.

Run it yourself

Every number above came from a query you can repeat. Ask the registry the same question for your own indication; the answer is drawn live, with its source and query time.

Try it on the live registryAI-assisted

AI reads your question into filters; every number comes straight from the ClinicalTrials.gov API at the moment you ask.

Method and queries

ClinicalTrials.gov API v2, pulled 17 Oct 2026. For each of 14 countries: condition "Crohn disease"; StudyType INTERVENTIONAL; LeadSponsorClass INDUSTRY; Phase 2 or 3; LocationCountry = country; overall status recruiting (competition) and completed (experience). Ratio = recruiting ÷ completed × 10.

Turn a registry question into a defensible decision.

Bring one live programme to an 8-week pilot. We build the board, freeze the evidence and run the decision session with you.

Plan a pilot